Artificial intelligence (AI) stands to drastically reduce both the risks and costs normally associated with the development of new medical products. This could fundamentally reshape pharmaceutical innovation, challenging both the justification for high medicines prices to recoup investment in research and development (R&D) and the market exclusivity systems – including patents and data exclusivity – which are used to maintain them.
A new research paper by Christopher Garrison posted 14 April on Medicines Law & Policy (ML&P), entitled ‘Pharmaceutical patents and data exclusivity in an age of Al-driven drug discovery and development,’ explores how AI might change R&D, and how this may affect the patent system
Leave a Reply